New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
11:33 EDTICPTIntercept trial of Obeticholic Acid posted on ClinicalTrials.gov
A trial of Intercept's Obeticholic Acid was posted on ClinicalTrials.gov, with a stated main purpose to test the drug' effectiveness when used in patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals with alcoholic hepatitis have certain abnormalities in how their body handles bile acids produced by the liver, the guidance said. Obeticholic acid has "been shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may improve liver condition in individuals with alcoholic hepatitis," the website notes. Shares of Intercept are up 10%, or $27.38, to $305.00 in late morning trading. Reference Link
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
15:22 EDTICPTIntercept CEO says company 'very well-positioned' in terms of balance sheet
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use